Our management team comprises individuals who have extensive multi-cultural experience in operations, preclinical and clinical development and financial matters. This team, pivoted in Singapore, will effectively manage the development plans through competent contract research organisations. 

Dr. Anil K Ratty, Chairman and CEO. 

More than 25 years in the area of neuroscience. Held various scientific and corporate positions in Buffalo General Hospital (USA) Roswell Park Cancer Institute (USA), Institute of Molecular and Cell Biology (Singapore), DMRI (Min of Defence, Singapore) Fisher Scientific SEA (Singapore). Founded several start-ups including Chakra Biotech (Singapore), Cerca Insights (Malaysia) and Cicada Cube (Singapore). Cerca Insights was sold to a US-based company in 2014. Co-inventor of several patents and has more than 20 scientific publications. Has worked in science and industry in the US, Japan, South-East Asia, India and China. 

Dr. Michael Entzeroth, Chief Scientific Officer/Chief Operating Officer.

He has more than 30 years of experience in pharmaceutical drug discovery and development. Between 2007 and 2013, he was Deputy Director of the A*STAR Experimental Therapeutics Centre.  As Scientific Officer of S*BIO Pte Ltd in Singapore, from 2003 to 2006, he generated three novel oncology drug candidates that reached clinical status. Between 1999 and 2002, as Vice President of CEREP SA in France, he was a member of the Executive Management Committee and responsible for the company’s pharmacology service and discovery activities. At Boehringer Ingelheim Germany, from 1985 to 1999, he was involved in a variety of drug discovery programs in cardiovascular and CNS research. He worked on a number of drugs reaching the clinics or the market, among them is Micardis®, an antihypertensive which achieved blockbuster sales since 2006. During his career, he published more than 50 papers in peer-reviewed scientific journals.